SCHEMBL2334937

SCHEMBL2334937

COc1cc(CN(C[C@H]2CCCC[C@@H]2O)S(=O)(=O)c2ccc(Cl)cc2)ccc1OCCc1scnc1C

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CXCR3 P49682 4/20 0.38
PSEN1 P49768 4/20 0.37
PSEN2 P49810 4/20 0.37
APH1B Q8WW43 4/20 0.37
NCSTN Q92542 4/20 0.37
APH1A Q96BI3 4/20 0.37
PSENEN Q9NZ42 4/20 0.37
TAS2R14 Q9NYV8 2/20 0.37
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36
HPGD P15428 1/20 0.36
TP53 P04637 1/20 0.36
KMT2A Q03164 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2335267 1.00 ALDH1A1 (0.41) ALDH1A1LMNASMN1; SMN2CXCR3PSEN1
SCHEMBL2335244 0.89 TP53 (0.44) ALDH1A1LMNASMN1; SMN2CXCR3PSEN1
SCHEMBL2339551 0.85 ALDH1A1 (0.48) ALDH1A1LMNASMN1; SMN2CXCR3HPGD
SCHEMBL2339348 0.84 ALDH1A1 (0.43) ALDH1A1LMNASMN1; SMN2TAS2R14HPGD
SCHEMBL2336215 0.84 ALDH1A1 (0.51) ALDH1A1LMNASMN1; SMN2PSEN1PSEN2
SCHEMBL2334245 0.83 ALDH1A1 (0.51) ALDH1A1LMNASMN1; SMN2PSEN1PSEN2
SCHEMBL2331291 0.83 ALDH1A1 (0.51) ALDH1A1LMNASMN1; SMN2PSEN1PSEN2
SCHEMBL2338966 0.83 MEN1 (0.42) ALDH1A1LMNASMN1; SMN2TAS2R14HPGD
SCHEMBL2340928 0.83 ALDH1A1 (0.50) ALDH1A1LMNASMN1; SMN2PSEN1PSEN2
SCHEMBL2332022 0.83 ALDH1A1 (0.39) ALDH1A1LMNASMN1; SMN2TAS2R14HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120270902-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-10-25 US claimed
US-20120270902-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-10-25 US disclosed
US-8193389-B2 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. (US) 2012-06-05 US disclosed
EP-2374792-A1 N-substituted benzene sulfonamides Elan Pharmaceuticals Inc. (US) 2011-10-12 EP disclosed
EP-2360142-A1 N-substituted benzene sulfonamides Elan Pharmaceuticals Inc. (US) 2011-08-24 EP disclosed
US-20050245573-A1 N-substituted benzene sulfonamides ELAN PHARMACEUTICALS, INC. 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245573-A1 N-substituted benzene sulfonamides PSEN1, PSEN2, BCHE ALDH1A1 665/4885LMNA 3051/4885SMN1; SMN2 148/4885
US-20120270902-A1 N-substituted benzene sulfonamides PSEN1, PSEN2, BCHE ALDH1A1 665/4885LMNA 3051/4885SMN1; SMN2 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.